The lack of sensitive and specific biomarkers for the early detection of prostate cancer (PCa) is a major hurdle to improve patient management. A metabolomics approach based on GC-MS was used to investigate the performance of volatile organic compounds (VOCs) in general and, more specifically, volatile carbonyl compounds (VCCs) present in urine as potential markers […]
There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. To develop consensus statements for all domains of DAT. A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and […]
There are no criteria for administering first- or second-generation anti-androgens (FGA and SGA, respectively) to patients with non-metastatic castration-resistant prostate cancer (nmCRPC). This study aimed to assess the efficacy of alternative FGA therapy in nmCRPC patients and the prognosis of these patients and to identify factors for predicting patients potentially responsive to FGA. Data from […]
Renal cell carcinoma(RCC) is one of the most common malignancies in kidney, and usually leads to poor prognosis. Therefore, identifying novel biomarkers for predicting the progression and prognosis of RCC is essential. The purpose of this study is aimed to evaluate the function of miR-221-5p in RCC and the clinical value of miR-221-5p in RCC […]
To determine the predictive value of preoperative neutrophil-to-lymphocyte ratio (NLR) for disease-free survival (DFS) in non-metastatic papillary renal cell carcinoma (pRCC) patients following partial or radical nephrectomy. We retrospectively analyzed 315 non-clear cell RCC patients who received curative surgery in our hospital from 2013 to 2018, from which 76 pRCC patients without metastasis (T1-3N0M0) were […]
No head-to-head clinical trials compare contemporary first-line therapies for metastatic renal cell carcinoma (mRCC). A network meta-analysis provides an approach for quantitative analysis. To indirectly compare the efficacy and safety of first-line treatments for mRCC in the intention-to-treat (ITT) population and by clinical risk group. An updated systematic review from database inception to February 17, […]
to evaluate possible predictors factors of testicular cancer (TC) in patients undergoing testicular sparing surgery (TSS). a retrospective analysis of all patients undergoing TSS for small testicular mass (STM) in five centers was performed. All patients with one solitary lesion ≤ 2cm at pre-operative ultrasound (US) were enrolled in the study. TSS consists in the […]
Phase II Randomized Placebo-Controlled Clinical Trial of Genistein in Reducing the Toxicity and Improving the Efficacy of Intravesical Therapy Condition: Bladder Cancer Intervention: Drug: Genistein Drug: Sugar pill Purpose: Patients with non-invasive bladder cancer are often treated with intravesical therapy in order to prevent the recurrence of bladder cancer. Intravesical therapy can cause many lower […]
Study of 18F-DCFPyL PET/CT, for Detection of Radiological Progression in Patients With Metastatic (M+) and Non-metastatic (M0) Castration Resistant Prostate Cancer Receiving Standard Androgen Receptor Targeted Treatment Condition: Prostate Cancer Intervention: Drug: 18F-DCFPyL Injection Purpose: This study evaluates the rate of radiological disease progression with the new 2nd generation positron emission tomography (PET) radiopharmaceutical, 18F-DCFPyL, […]
PSMA-PET Guided Radiotherapy in Patients With High-Risk, Recurrent, or Oligometastatic Prostate Cancer Condition: Prostate Cancer Intervention: Radiation: PSMA -PET/CT simulation Radiation: Standard-care simulation Purpose: PSMA PET/CT has demonstrated higher sensitivity in detecting metastases than current imaging standard of care (CT and bone scan). [18F]DCFPyL is a promising high-sensitivity second generation PSMA-targeted urea-based PET probe. The […]
